Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Ingram joins Allergan’s board

Executive Summary

GlaxoSmithKline Vice Chairman-Pharmaceuticals Bob Ingram is joining Allergan's board of directors. He sits on the board of several corporations, including Edwards Lifesciences and Lowe's, as well as serving as chairman of the board of OSI Pharmaceuticals (1"The Pink Sheet" Jan. 13, 2003, In Brief). Ingram's relationship with Allergan is somewhat noteworthy as both Allergan and GSK are members of the Pharmaceutical Research & Manufacturers of America...

You may also be interested in...

OSI hires GSK’s Ingram

GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram joins OSI Pharmaceuticals as chairman of board of directors in a non-executive capacity, effective Jan. 1. "Ingram will assume chairmanship of the Board's executive, nominating and compensation committees," OSI said. OSI CEO Colin Goddard relinquishes chairmanship of board. Ingram retired as GSK chief operating officer and pharmaceutical operations president in December (1"The Pink Sheet" Oct. 21, 2002, p. 27)...

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts